We are live on ! Find out more
HBIO icon

Harvard Bioscience

84 hedge funds and large institutions have $129M invested in Harvard Bioscience in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

12% more capital invested

Capital invested by funds: $116M → $129M (+$13.3M)

6% more funds holding

Funds holding: 7984 (+5)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $54K

Holders
84
Holders Change
+5
Holders Change %
+6.33%
% of All Funds
2.26%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
18
Increased
28
Reduced
25
Closed
13
Calls
Puts
$54K
Net Calls
-$54K
Net Calls Change
-$61K
Name Holding Trade Value Shares
Change
Change in
Stake
TA
51
Teachers Advisors
New York
$267K +$267K +4,685 New
SIM
52
Spark Investment Management
New York
$215K
RFC
53
Russell Frank Company
Washington
$190K -$23.7K -416 -11%
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$188K +$188K +3,306 New
DIA
55
Denver Investment Advisors
Colorado
$178K +$178K +3,123 New
NFA
56
Nationwide Fund Advisors
Ohio
$165K +$114K +2,002 +226%
T. Rowe Price Associates
57
T. Rowe Price Associates
Maryland
$161K
Asset Management One
58
Asset Management One
Japan
$147K
Two Sigma Advisers
59
Two Sigma Advisers
New York
$125K -$13.1K -230 -9%
AIG
60
American International Group
New York
$112K +$112K +1,960 New
D.E. Shaw & Co
61
D.E. Shaw & Co
New York
$110K -$78.7K -1,383 -42%
Two Sigma Investments
62
Two Sigma Investments
New York
$107K -$44.4K -780 -29%
Goldman Sachs
63
Goldman Sachs
New York
$104K -$8.48K -149 -8%
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$98K +$98.3K +1,727 New
Citadel Advisors
65
Citadel Advisors
Florida
$93K +$92K +1,616 New
Balyasny Asset Management
66
Balyasny Asset Management
Illinois
$88K +$8.31K +146 +10%
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$80K +$11.8K +207 +17%
EGA
68
Eagle Global Advisors
Texas
$67K -$82.2K -1,445 -55%
CS
69
Credit Suisse
Switzerland
$61K -$244K -4,295 -80%
Morgan Stanley
70
Morgan Stanley
New York
$59K -$295K -5,176 -83%
Deutsche Bank
71
Deutsche Bank
Germany
$45K -$178K -3,123 -80%
JC
72
JBF Capital
Colorado
$35K
MA
73
MUFG Americas
New York
$20K
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$15.9K +$15.8K +278 New
EARNEST Partners
75
EARNEST Partners
Georgia
$15K

HBIO Hedge Fund Activity: Q2 2015 in Review

84 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2015, worth a combined $129M — up 12% from $116M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new HBIO positions and 13 closed out — a net gain of 5 holders — while 28 added to existing stakes and 25 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $4.42M. The largest seller was Penbrook Management, cutting an estimated $1.62M.

  • 84 institutional investors held Harvard Bioscience (HBIO) as of Q2 2015, up from 79 in Q1 2015.
  • Funds reported $129M of Harvard Bioscience stock for Q2 2015, up 12% quarter-over-quarter.
  • 18 funds opened new Harvard Bioscience positions in Q2 2015 and 13 closed out, a net change of +5 holders.
  • The largest Harvard Bioscience buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $4.42M added.
  • The largest Harvard Bioscience seller in Q2 2015 was Penbrook Management, an estimated $1.62M sold.

Based on aggregated 13F filings for Q2 2015.